New clinical study expands on LPLDL® efficacy in adults with coeliac disease and demonstrates improvements in key cardiometabolic biomarkers
ProBiotix Health, a life sciences company developing pioneering probiotic solutions for cardiometabolic health, has announced the publication of a new pilot human intervention study demonstrating the efficacy of its patented probiotic strain Lactobacillus plantarum ECGC 13110402, LPLDL®, in adults with coeliac disease (CeD) and hypercholesterolaemia. It is the first published clinical investigation evaluating LPLDL® in this patient population. The randomised, placebo-controlled pilot […]